1. Netherlands Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
argenx SE

argenx SE

ARGNF
argenx SEUS flagOther OTC
936.00
USD
-15.43
- -
58.21BMarket Cap
argenx SE
ARGNF
(Other OTC)

Recent

price

936.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.09
0.14
0.24
0.6
0.48
0.82
1.78
0.68
2.03
0.91
9.74
7.55
21.45
36.59
67.76
84.24
Revenue per Share
- -
-0.29
-0.82
-0.54
-1.66
-1.06
-1.19
-1.37
-2.12
-4.69
-13.4
-7.99
-13.05
-5.16
13.92
21.08
27.64
Basic EPS, GAAP
- -
-0.27
-0.71
-0.59
-0.87
-0.99
0.54
-1.8
-1.73
2.72
-8.89
-14.26
-17.78
-8.12
-2.52
9.36
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.65
1.78
1.06
1.91
3.88
2.58
3.31
12.86
17.12
27.6
35.19
49.05
50.79
69.22
90.49
118.34
134.59
Book Value per Share
0.65
1.78
1.06
1.91
3.88
2.58
3.31
12.86
17.12
26.55
31.67
45.73
47.64
67.11
87.5
113.94
130.34
Tangible Book Value per Share
- -
16
16
16
8
16
19
25
36
39
45
51
54
57
60
61
62
Basic Weighted Avg Shares
- -
1
2
4
5
7
15
44
25
78
41
497
411
1,226
2,190
4,153
5,228
Sales/Revenue/Turnover
- -
-323.64
-608.78
-232.69
-286.02
-227.68
-145.56
-62.97
-381.01
-255.04
-1,165.21
-72.37
-176.24
-34.3
-0.81
25.39
30.56
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
1
2
4
6
104
111
18
28
- -
Depreciation Expense
- -
-4
-13
-8
-13
-17
-22
-34
-76
-181
-608
-408
-710
-295
833
1,292
1,715
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.78
Effective Tax Rate (%)
- -
-308
-587.4
-229.03
-274.6
-223.4
-145.27
-77.1
-310.22
-230.95
-1,475.29
-82.1
-172.76
-24.06
38.03
31.11
32.81
Profit Margin (%)
10
28
16
29
60
39
73
411
609
1,363
1,729
2,242
2,472
3,701
4,213
5,579
6,493
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
6
8
9
15
33
36
36
LT Debt
10
28
17
30
61
41
67
414
616
1,180
1,674
2,534
2,814
4,098
5,498
7,323
8,417
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
21.39
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
23.54
Return on Capital (%)
- -
-23.56
-57.58
-36.32
-27.6
-32.94
-41.86
-14.02
-14.81
-20.18
-42.63
-19.4
-26.54
-8.54
17.36
20.15
23.64
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11
- -
11
LT Borrowings
- -
- -
- -
LT Finance Leases
36
- -
36
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
62
63
Market Capitalization
53,838
44,063
56,284

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,899
- -
8,068
Cash, Cash Equivalents & STI
4,440
- -
5,184
Accounts Receivable, Net
1,490
- -
1,832
Inventories
474
- -
371
Total Current Liabilities
1,320
- -
1,575
Payables & Accruals
695
- -
925
ST Debt
11
- -
11
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
94.21%
35.08%
33.19%
Free Cash Flow
-189.63%
-97.19%
-479.69%
Net Income, GAAP
23.92%
-68.95%
55.1%
Sales/Revenue/Turnover
187.2%
291.02%
89.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
401
478
573
738
2,190
2025
790
948
1,127
1,288
4,153
2026
1,298
1,515
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.04
- -
1.52
- -
13.92
2025
2.77
- -
- -
- -
21.08
2026
5.9
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Finch Therapeutics Group, Inc. (FNCH)
EirGenix, Inc. (6589.TW)
Oncocross Co., Ltd. (382150.KQ)
Frequency Therapeutics, Inc. (FREQ)
Ovoca Bio plc (OVXA.IR)
Lyra Therapeutics, Inc. (LYRA)
Business
argenx SE, a global immunology company headquartered in Amsterdam, Netherlands, and founded in 2008, develops and commercializes antibody-based therapies targeting severe autoimmune diseases; its lead product, VYVGART (efgartigimod), an FcRn inhibitor available in intravenous and subcutaneous formulations including VYVGART Hytrulo and pre-filled syringe, treats generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP); the company advances a broad pipeline through its Immunology Innovation Program (IIP), encompassing candidates like ARGX-109, ARGX-213, and ARGX-121 in clinical stages for additional autoimmune indications such as primary immune thrombocytopenia (ITP), thyroid eye disease, and Sjogren's syndrome, with out-licensed assets including LP0145 (ARGX-112) to LEO Pharma, ARGX-115 (ABBV-151) to AbbVie, and collaborations with Genmab. argenx operates across the United States, Europe, Japan, China, and emerging markets including the Gulf region via partners like Zai Lab and Genpharm, serving patients and healthcare providers with precision medicines derived from proprietary antibody engineering platforms. Recent developments include expansion of the global collaboration with Halozyme Therapeutics in September 2024 to six targets incorporating ENHANZE drug delivery technology; a new strategic partnership with Unnatural Products in 2025 to develop oral peptides; an expanded manufacturing agreement with FUJIFILM for a North Carolina facility supporting efgartigimod supply; regulatory progress with Phase 1 data for ARGX-109 expected in late 2025 and further topline results for pipeline programs through 2026; and robust commercial growth with global VYVGART net sales reaching $949 million in Q2 2025, up 97% year-over-year, alongside FDA PDUFA target for VYVGART SC pre-filled syringe in April 2025.

Company News

Company News APIChatGPT

  • businesswire.com

    Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

  • businesswire.com

    BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery

  • wsj.com

    Argenx to Buy Forte Biosciences for $2.2 Billion

  • reuters.com

    Argenx to buy Forte Biosciences for about $2.2 billion

  • reuters.com

    Argenx's Vyvgart sales jump in second quarter

  • investors.com

    Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

  • seekingalpha.com

    argenx SE (ARGX) Q1 2026 Earnings Call Transcript